Resultados da busca - Pèlegrin, Andre
- Mostrando 1 - 20 resultados de 43
- Ir para a próxima página
-
1
-
2
Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6(th) antibody industrial symposium, June 25-26, 2018, Montpellier, France por Martineau, Pierre, Watier, Hervé, Pèlegrin, Andre, Turtoi, Andrei
Publicado em 2019Texto -
3
Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures por Larbouret, Christel, Gros, Laurent, Pèlegrin, André, Chardès, Thierry
Publicado em 2021Texto -
4
-
5
-
6
Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France por Martin, Camille, Kizlik-Masson, Claire, Pèlegrin, André, Watier, Hervé, Viaud-Massuard, Marie-Claude, Joubert, Nicolas
Publicado em 2018Texto -
7
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficki... por Lanotte, Romain, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Musnier, Astrid, Martineau, Pierre, Pèlegrin, André, Chardès, Thierry
Publicado em 2020Texto -
8
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers por Garambois, Véronique, Glaussel, Fabienne, Foulquier, Elodie, Ychou, Marc, Pugnière, Martine, Luo, Robin X, Bezabeh, Binyam, Pèlegrin, André
Publicado em 2004Texto -
9
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein por Germain, Claire, Campigna, Emmanuelle, Salhi, Imed, Morisseau, Sébastien, Navarro-Teulon, Isabelle, Mach, Jean-Pierre, Pèlegrin, André, Robert, Bruno
Publicado em 2008Texto -
10
Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity por Lacombe, Jérôme, Brengues, Muriel, Mangé, Alain, Bourgier, Céline, Gourgou, Sophie, Pèlegrin, André, Ozsahin, Mahmut, Solassol, Jérôme, Azria, David
Publicado em 2019Texto -
11
Improving Patients’ Life Quality after Radiotherapy Treatment by Predicting Late Toxicities por Lapierre, Ariane, Bourillon, Laura, Larroque, Marion, Gouveia, Tiphany, Bourgier, Céline, Ozsahin, Mahmut, Pèlegrin, André, Azria, David, Brengues, Muriel
Publicado em 2022Texto -
12
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation por Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Larbouret, Christel, Poul, Marie-Alix, Mondon, Philippe, Melino, Gerry, Pèlegrin, André, Chardès, Thierry
Publicado em 2016Texto -
13
Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients por Framery, Bérénice, Gutowski, Marian, Dumas, Karen, Evrard, Alexandre, Muller, Nathalie, Dubois, Vincent, Quinonero, Jérôme, Scherninski, François, Pèlegrin, André, Cailler, Françoise
Publicado em 2019Texto -
14
Letrozole sensitizes breast cancer cells to ionizing radiation por Azria, David, Larbouret, Christel, Cunat, Severine, Ozsahin, Mahmut, Gourgou, Sophie, Martineau, Pierre, Evans, Dean B, Romieu, Gilles, Pujol, Pascal, Pèlegrin, Andre
Publicado em 2005Texto -
15
Neutralization of KIT oncogenic signaling in leukemia with antibodies targeting KIT membrane proximal domain 5 por Le Gall, Marianne, Crépin, Ronan, Neiveyans, Madeline, Auclair, Christian, Fan, Yongfeng, Zhou, Yu, Marks, James D., Pèlegrin, André, Poul, Marie-Alix
Publicado em 2015Texto -
16
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptor... por Larbouret, Christel, Gaborit, Nadège, Chardès, Thierry, Coelho, Mickaël, Campigna, Emmanuelle, Bascoul-Mollevi, Caroline, Mach, Jean-Pierre, Azria, David, Robert, Bruno, Pèlegrin, André
Publicado em 2012Texto -
17
Symplekin promotes tumorigenicity by up-regulating claudin-2 expression por Buchert, Michael, Papin, Marina, Bonnans, Caroline, Darido, Charbel, Raye, Warren S., Garambois, Véronique, Pélegrin, André, Bourgaux, Jean-François, Pannequin, Julie, Joubert, Dominique, Hollande, Frédéric
Publicado em 2010Texto -
18
Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis por Santoro, Lore, Boutaleb, Samir, Garambois, Véronique, Bascoul-Mollevi, Caroline, Boudousq, Vincent, Kotzki, Pierre-Olivier, Pèlegrin, Monique, Navarro-Teulon, Isabelle, Pèlegrin, André, Pouget, Jean-Pierre
Publicado em 2009Texto -
19
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer por Azria, David, Bibeau, Frederic, Barbier, Nicolas, Zouhair, Abderrahim, Lemanski, Claire, Rouanet, Philippe, Ychou, Marc, Senesse, Pierre, Ozsahin, Mahmut, Pèlegrin, André, Dubois, Jean-Bernard, Thèzenas, Simon
Publicado em 2005Texto -
20
Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers: A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONO... por Gaborit, Nadège, Larbouret, Christel, Vallaghe, Julie, Peyrusson, Frédéric, Bascoul-Mollevi, Caroline, Crapez, Evelyne, Azria, David, Chardès, Thierry, Poul, Marie-Alix, Mathis, Gérard, Bazin, Hervé, Pèlegrin, André
Publicado em 2011Texto